Bulleyaconitine ACAS# 107668-79-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 107668-79-1 | SDF | Download SDF |
PubChem ID | 159311 | Appearance | White powder |
Formula | C35H49NO9 | M.Wt | 627.78 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | DMSO : 125 mg/mL (199.12 mM; Need ultrasonic) | ||
SMILES | CCN1CC2(CCC(C34C2C(C(C31)C5(CC(C6(CC4C5C6C(=O)C7=CC=C(C=C7)OC)O)OC)OC(=O)C)OC)OC)COC | ||
Standard InChIKey | YRECILNLFWZVRM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C35H49NO9/c1-8-36-17-32(18-40-3)14-13-23(42-5)35-22-15-33(39)24(43-6)16-34(45-19(2)37,27(31(35)36)29(44-7)30(32)35)25(22)26(33)28(38)20-9-11-21(41-4)12-10-20/h9-12,22-27,29-31,39H,8,13-18H2,1-7H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Bulleyaconitine A is an analgesic and antiinflammatory drug, it has several potential targets, including voltage-gated Na+ channels. It displays long-acting local anesthetic properties in vitro and in vivo, it has been approved for the treatment of chronic pain and rheumatoid arthritis in China, it has the suppressive effect on some immune function of Balb/c mice. |
Targets | NO | Sodium Channel |
In vitro | Bulleyaconitine A isolated from aconitum plant displays long-acting local anesthetic properties in vitro and in vivo.[Pubmed: 17585219]Anesthesiology. 2007 Jul;107(1):82-90.Bulleyaconitine A (BLA) is an active ingredient of Aconitum bulleyanum plants. Bulleyaconitine A has been approved for the treatment of chronic pain and rheumatoid arthritis in China, but its underlying mechanism remains unclear.
|
In vivo | Bulleyaconitine A depresses neuropathic pain and potentiation at C-fiber synapses in spinal dorsal horn induced by paclitaxel in rats.[Pubmed: 26376216 ]Exp Neurol. 2015 Nov;273:263-72.Paclitaxel, a widely used chemotherapeutic agent, often induces painful peripheral neuropathy and at present no effective drug is available for treatment of the serious side effect.
Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat.[Pubmed: 18806059]Anesth Analg. 2008 Oct;107(4):1397-405.Bulleyaconitine A (BLA) is an analgesic and antiinflammatory drug isolated from Aconitum plants. BLA has several potential targets, including voltage-gated Na+ channels. We tested whether BLA elicited long-lasting cutaneous analgesia, when co-injected with lidocaine and epinephrine, as a model for prolonged infiltration anesthesia.
|
Animal Research | Inhibitory effect of bulleyaconitine A on some immune function in Balb/c mice.[Reference: WebLink]Chinese Journal of New Drugs & Clinical Remedies, 2007, 26(10):755-8.To determine the effect of Bulleyaconitine A(BLA)on some immune functions of mice.
|
Bulleyaconitine A Dilution Calculator
Bulleyaconitine A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.5929 mL | 7.9646 mL | 15.9291 mL | 31.8583 mL | 39.8229 mL |
5 mM | 0.3186 mL | 1.5929 mL | 3.1858 mL | 6.3717 mL | 7.9646 mL |
10 mM | 0.1593 mL | 0.7965 mL | 1.5929 mL | 3.1858 mL | 3.9823 mL |
50 mM | 0.0319 mL | 0.1593 mL | 0.3186 mL | 0.6372 mL | 0.7965 mL |
100 mM | 0.0159 mL | 0.0796 mL | 0.1593 mL | 0.3186 mL | 0.3982 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Merucathinone
Catalog No.:BCN1783
CAS No.:107638-80-2
- Erycibelline
Catalog No.:BCN1876
CAS No.:107633-95-4
- Dehydroformouregine
Catalog No.:BCN4054
CAS No.:107633-69-2
- PF 998425
Catalog No.:BCC7811
CAS No.:1076225-27-8
- 4-Hydroxycoumarin
Catalog No.:BCN2561
CAS No.:1076-38-6
- 4-Demethyl-3,9-dihydroeucomin
Catalog No.:BCN5876
CAS No.:107585-77-3
- 3'-Hydroxy-3,9-dihydroeucomin
Catalog No.:BCN5875
CAS No.:107585-75-1
- Anwulignan
Catalog No.:BCN5362
CAS No.:107534-93-0
- Omadacycline tosylate
Catalog No.:BCC5136
CAS No.:1075240-43-5
- Glucagon-like peptide 1 (7-36) amide (human, rat)
Catalog No.:BCC7258
CAS No.:107444-51-9
- Bisabola-2,10-diene-1,9-dione
Catalog No.:BCN7269
CAS No.:107439-25-8
- Ginkgolide J
Catalog No.:BCN5939
CAS No.:107438-79-9
- Merucathine
Catalog No.:BCN1782
CAS No.:107673-74-5
- beta-Lipoic acid
Catalog No.:BCC9198
CAS No.:6992-30-9
- MDL 11,939
Catalog No.:BCC6822
CAS No.:107703-78-6
- Epleremone
Catalog No.:BCC3776
CAS No.:107724-20-9
- Methyl 7beta,15-dihydroxydehydroabietate
Catalog No.:BCN7270
CAS No.:107752-10-3
- Zafirlukast
Catalog No.:BCC4881
CAS No.:107753-78-6
- A 61603 hydrobromide
Catalog No.:BCC6912
CAS No.:107756-30-9
- Coccinic acid
Catalog No.:BCN5877
CAS No.:107783-45-9
- 3,4-Dihydroxybenzenepropanoic acid
Catalog No.:BCN8500
CAS No.:1078-61-1
- PF 04418948
Catalog No.:BCC6299
CAS No.:1078166-57-0
- Exemestane
Catalog No.:BCC1061
CAS No.:107868-30-4
- Quinovin
Catalog No.:BCN5878
CAS No.:107870-05-3
Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat.[Pubmed:18806059]
Anesth Analg. 2008 Oct;107(4):1397-405.
BACKGROUND: Bulleyaconitine A (BLA) is an analgesic and antiinflammatory drug isolated from Aconitum plants. BLA has several potential targets, including voltage-gated Na+ channels. We tested whether BLA elicited long-lasting cutaneous analgesia, when co-injected with lidocaine and epinephrine, as a model for prolonged infiltration anesthesia. METHODS: The local anesthetic properties of BLA were assessed by the patch-clamp technique in HEK293t cells expressing Nav1.7 and Nav1.8 neuronal Na+ channels, both crucial for nociception. Drug solutions (0.6 mL) were injected subcutaneously via rat shaved dorsal skin. Inhibition of the cutaneous trunci muscle reflex was evaluated by pinpricks. Skin cross-sections were stained with hematoxylin and eosin or with antibodies against PGP9.5. RESULTS: BLA at 10 microM interacted minimally with resting or inactivated Nav1.7 and Nav1.8 Na+ channels when infrequently stimulated to +50 mV for 3 ms. However, when stimulated at 2 Hz for 1000 pulses, their peak Na+ currents were >90% reduced by BLA. This use-dependent inhibition was not significantly reversed after 15-min washing. Complete nociceptive blockade after injection of lidocaine (0.5%)/epinephrine (1:200,000) lasted for approximately 1 h in rats; full recovery occurred after approximately 6 h. Co-injection of 0.125 mM BLA with lidocaine/epinephrine increased the duration of complete nociceptive blockade to 24 h. Full recovery occurred after approximately 6 days. Skin histology including peripheral nerve fibers appeared unaffected by BLA. CONCLUSIONS: BLA inhibits Nav1.7 and Nav1.8 Na+ currents in a use-dependent manner. Co-injection of BLA at BACKGROUND: Bulleyaconitine A (BLA) is an active ingredient of Aconitum bulleyanum plants. BLA has been approved for the treatment of chronic pain and rheumatoid arthritis in China, but its underlying mechanism remains unclear. METHODS: The authors examined (1) the effects of BLA on neuronal voltage-gated Na channels in vitro under the whole cell patch clamp configuration and (2) the sensory and motor functions of rat sciatic nerve after single BLA injections in vivo. RESULTS: BLA at 10 microm did not affect neuronal Na currents in clonal GH3 cells when stimulated infrequently to +50 mV. When stimulated at 2 Hz for 1,000 pulses (+50 mV for 4 ms), BLA reduced the peak Na currents by more than 90%. This use-dependent reduction of Na currents by BLA reversed little after washing. Single injections of BLA (0.2 ml at 0.375 mm) into the rat sciatic notch not only blocked sensory and motor functions of the sciatic nerve but also induced hyperexcitability, followed by sedation, arrhythmia, and respiratory distress. When BLA at 0.375 mm was coinjected with 2% lidocaine (approximately 80 mm) or epinephrine (1:100,000) to reduce drug absorption by the bloodstream, the sensory and motor functions of the sciatic nerve remained fully blocked for approximately 4 h and regressed completely after approximately 7 h, with minimal systemic effects. CONCLUSIONS: BLA reduces neuronal Na currents strongly at +50 mV in a use-dependent manner. When coinjected with lidocaine or epinephrine, BLA elicits prolonged block of both motor and sensory functions in rats with minimal adverse effects. Paclitaxel, a widely used chemotherapeutic agent, often induces painful peripheral neuropathy and at present no effective drug is available for treatment of the serious side effect. Here, we tested if intragastrical application of Bulleyaconitine A (BLA), which has been approved for clinical treatment of chronic pain in China since 1985, could relieve the paclitaxel-induced neuropathic pain. A single dose of BLA attenuated the mechanical allodynia, thermal hyperalgesia induced by paclitaxel dose-dependently. Repetitive administration of the drug (0.4 and 0.8 mg/kg, t.i.d. for 7 d) during or after paclitaxel treatment produced a long-lasting inhibitory effect on thermal hyperalgesia, but not on mechanical allodynia. In consistency with the behavioral results, in vivo electrophysiological experiments revealed that spinal synaptic transmission mediated by C-fiber but not A fiber was potentiated, and the magnitude of long-term potentiation (LTP) at C-fiber synapses induced by the same high frequency stimulation was ~50% higher in paclitaxel-treated rats, compared to the naive rats. Spinal or intravenous application of BLA depressed the spinal LTP, dose-dependently. Furthermore, patch clamp recordings in spinal cord slices revealed that the frequency but not amplitude of both spontaneous excitatory postsynaptic current (sEPSCs) and miniature excitatory postsynaptic currents (mEPSCs) in lamina II neurons was increased in paclitaxel-treated rats, and the superfusion of BLA reduced the frequency of sEPSCs and mEPSCs in paclitaxel-treated rats but not in naive ones. Taken together, we provide novel evidence that BLA attenuates paclitaxel-induced neuropathic pain and that depression of spinal LTP at C-fiber synapses via inhibiting presynaptic transmitter release may contribute to the effect.Bulleyaconitine A isolated from aconitum plant displays long-acting local anesthetic properties in vitro and in vivo.[Pubmed:17585219]
Anesthesiology. 2007 Jul;107(1):82-90.
Bulleyaconitine A depresses neuropathic pain and potentiation at C-fiber synapses in spinal dorsal horn induced by paclitaxel in rats.[Pubmed:26376216]
Exp Neurol. 2015 Nov;273:263-72.